Explainable Artificial Intelligence for Drug Discovery and Development -- A Comprehensive Survey
Authors:
Roohallah Alizadehsani,
Solomon Sunday Oyelere,
Sadiq Hussain,
Rene Ripardo Calixto,
Victor Hugo C. de Albuquerque,
Mohamad Roshanzamir,
Mohamed Rahouti,
Senthil Kumar Jagatheesaperumal
Abstract:
The field of drug discovery has experienced a remarkable transformation with the advent of artificial intelligence (AI) and machine learning (ML) technologies. However, as these AI and ML models are becoming more complex, there is a growing need for transparency and interpretability of the models. Explainable Artificial Intelligence (XAI) is a novel approach that addresses this issue and provides…
▽ More
The field of drug discovery has experienced a remarkable transformation with the advent of artificial intelligence (AI) and machine learning (ML) technologies. However, as these AI and ML models are becoming more complex, there is a growing need for transparency and interpretability of the models. Explainable Artificial Intelligence (XAI) is a novel approach that addresses this issue and provides a more interpretable understanding of the predictions made by machine learning models. In recent years, there has been an increasing interest in the application of XAI techniques to drug discovery. This review article provides a comprehensive overview of the current state-of-the-art in XAI for drug discovery, including various XAI methods, their application in drug discovery, and the challenges and limitations of XAI techniques in drug discovery. The article also covers the application of XAI in drug discovery, including target identification, compound design, and toxicity prediction. Furthermore, the article suggests potential future research directions for the application of XAI in drug discovery. The aim of this review article is to provide a comprehensive understanding of the current state of XAI in drug discovery and its potential to transform the field.
△ Less
Submitted 2 November, 2023; v1 submitted 21 September, 2023;
originally announced September 2023.
Effective Class-Imbalance learning based on SMOTE and Convolutional Neural Networks
Authors:
Javad Hassannataj Joloudari,
Abdolreza Marefat,
Mohammad Ali Nematollahi,
Solomon Sunday Oyelere,
Sadiq Hussain
Abstract:
Imbalanced Data (ID) is a problem that deters Machine Learning (ML) models for achieving satisfactory results. ID is the occurrence of a situation where the quantity of the samples belonging to one class outnumbers that of the other by a wide margin, making such models learning process biased towards the majority class. In recent years, to address this issue, several solutions have been put forwar…
▽ More
Imbalanced Data (ID) is a problem that deters Machine Learning (ML) models for achieving satisfactory results. ID is the occurrence of a situation where the quantity of the samples belonging to one class outnumbers that of the other by a wide margin, making such models learning process biased towards the majority class. In recent years, to address this issue, several solutions have been put forward, which opt for either synthetically generating new data for the minority class or reducing the number of majority classes for balancing the data. Hence, in this paper, we investigate the effectiveness of methods based on Deep Neural Networks (DNNs) and Convolutional Neural Networks (CNNs), mixed with a variety of well-known imbalanced data solutions meaning oversampling and undersampling. To evaluate our methods, we have used KEEL, breast cancer, and Z-Alizadeh Sani datasets. In order to achieve reliable results, we conducted our experiments 100 times with randomly shuffled data distributions. The classification results demonstrate that the mixed Synthetic Minority Oversampling Technique (SMOTE)-Normalization-CNN outperforms different methodologies achieving 99.08% accuracy on the 24 imbalanced datasets. Therefore, the proposed mixed model can be applied to imbalanced binary classification problems on other real datasets.
△ Less
Submitted 13 October, 2022; v1 submitted 1 September, 2022;
originally announced September 2022.
